Hepatitis B Virus (HBV) Vaccine

Hepatitis B

About Hepatitis B

Hepatitis is a serious disease caused by a several types of viruses that attack the liver. The virus called hepatitis B virus (HBV) can cause lifelong infection, inflammation of the liver, cirrhosis (scarring) of the liver, liver cancer, liver failure, and death. HBV is a blood-borne viral disease that can infect newborns through mother-to-child transmission during delivery and adults primarily through  sexual contact, sharing contaminated needles among drug users, and accidental exposure to HBV-contaminated blood (needle-sticks) in healthcare settings. For more information and a world map showing the prevalence of Hepatitis B, click here.

A therapeutic vaccine for chronic hepatitis B

Altravax’s lead product is a novel therapeutic vaccine for treating chronic infection by the hepatitis B virus (HBV), a disease that kills over one million people each year with 4,000 deaths in the US. There is no cure for the 350 million people worldwide who are infected with HBV and at increased risk of liver disease, notably cirrhosis and liver cancer. For the 1.3 million carriers in the U.S., the direct costs of chronic HBV infection to the medical system (outpatient visits and hospitalization) are substantial, and are estimated to be in excess of $1 billion per year.

Altravax’s therapeutic vaccine, developed through use of our IOS technology, is highly differentiated from the product candidates previously evaluated for treatment of chronic HBV infections. Altravax’s preclinical studies in animals indicate that our product can be an effective therapeutic vaccine for chronic HBV.

Treatment of the on-going infection with a vaccine that stimulates the immune system will be a more effective alternative to current therapies and addresses the real need for viral clearance from the bloodstream and, ultimately, a cure.

Development Status

This product has entered formal preclinical development to perform the manufacturing and safety studies needed for submission of an IND application to the US FDA.